title: Tamoxifen-SSRIs interaction: clinical manifestations of inhibition and lack of inhibition of CYP2D6.
authors.forename: Francisco
authors.initials: F
authors.lastname: Appiani
authors.forename: Brendan T
authors.initials: BT
authors.lastname: Carroll
authors.forename: Camilo
authors.initials: C
authors.lastname: Muñoz
authors.forename: Juan
authors.initials: J
authors.lastname: Trecco
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000523:psychology*; D044584:Carcinoma, Ductal / Q000188:drug therapy* / Q000523:psychology*; D015283:Citalopram / Q000009:adverse effects* / Q000627:therapeutic use; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000523:psychology*; D004347:Drug Interactions; D005260:Female; D019584:Hot Flashes / Q000139:chemically induced; D006801:Humans; D008875:Middle Aged; D017374:Paroxetine / Q000009:adverse effects* / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D015283:Citalopram; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors; D013629:Tamoxifen